REX-8756 / Recludix Pharma, Sanofi - LARVOL DELTA

Recludix Pharma Advances First-in-Class Oral STAT6 Inhibitor REX-8756 for Inflammatory Diseases, Including Atopic Dermatitis (DermatologyTimes) - "The announcement coincides with the completion of Good Laboratory Practice (GLP) toxicology studies for the candidate, a milestone that initiated a $50 million payment under the company’s collaboration with Sanofi...Recludix reports that REX-8756 exhibits complete STAT6 pathway inhibition in vitro and in vivo, durable target engagement without requiring continuous high plasma exposure, potent suppression of IL-4/IL-13-induced biomarkers, and efficacy in murine models of asthma, acute lung inflammation, and dermatitis...With Investigational New Drug (IND)-enabling studies underway, Recludix plans to submit an IND application later in 2025."

IND • Preclinical • Asthma • Dermatitis • Immunology • Inflammation